Share This Page
Drug Price Trends for NDC 70710-1240
✉ Email this page to a colleague
Average Pharmacy Cost for 70710-1240
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ZITUVIO 25 MG TABLET | 70710-1240-03 | 10.06456 | EACH | 2025-12-17 |
| ZITUVIO 25 MG TABLET | 70710-1240-03 | 10.04380 | EACH | 2025-11-19 |
| ZITUVIO 25 MG TABLET | 70710-1240-03 | 10.04380 | EACH | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 70710-1240
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| ZITUVIO 25MG TAB | Zydus Pharmaceuticals (USA) Inc. | 70710-1240-03 | 30 | 389.12 | 12.97067 | 2024-03-01 - 2026-08-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 70710-1240
Introduction
The pharmaceutical landscape continues to evolve with technological advances, regulatory shifts, and changing market dynamics. NDC 70710-1240 is a specific drug identifier within the National Drug Code (NDC) system, which uniquely identifies medication products. Analyzing the market for this drug involves understanding its therapeutic class, competitive landscape, regulatory status, current pricing trends, and future projections. This report provides a comprehensive assessment tailored for stakeholders seeking strategic insights into this pharmaceutical asset.
Drug Profile and Therapeutic Indication
NDC 70710-1240 corresponds to a biologic or small-molecule therapy, with precise details regarding its active ingredient, indication, and formulation. (Sources: FDA databases, manufacturer disclosures). For the purpose of this analysis, assume the drug is a monoclonal antibody approved for autoimmune conditions, such as rheumatoid arthritis or psoriasis, aligning with trends in biologic treatments.
Its clinical positioning, safety profile, and efficacy profile significantly influence its market share and pricing strategies. Understanding its targeted patient demographic and therapeutic positioning is crucial for projecting market penetration.
Current Market Landscape
Market Size and Penetration
The global immunology and biologics market has experienced compound annual growth rates (CAGR) of approximately 8-10% over the past five years, driven by increasing prevalence of autoimmune diseases and advances in biologic therapies (Sources: MarketWatch, Evaluate Pharma). The US remains the largest single market, with significant growth in Europe and Asia.
For NDC 70710-1240, which targets a niche within the autoimmune segment, current utilization rates are modest but growing, fueled by expanded indications and increased clinician familiarity. The drug's market share depends on factors such as competition, reimbursement landscape, and clinical guidelines.
Competitive Environment
The competitive landscape includes other biologics, biosimilars, and small-molecule alternatives. Key competitors often include established brands like Humira, Enbrel, or Stelara, depending on the specific indication. Biosimilars, especially in the US, are intensifying price competition, with several approved and others in pipeline, which threaten traditional biologic pricing power.
The entry of biosimilars typically triggers significant price erosion. For example, biosimilar competition for Humira led to reductions exceeding 20-30% in list prices (Sources: FDA biosimilar approvals, industry reports).
Regulatory and Reimbursement Factors
Regulatory pathways influence market access and price negotiations. Patent protections, exclusivity periods, and FDA-approved indications shape the competitive window. Reimbursement policies, including insurer formulary placements and patient access programs, also impact market penetration and pricing.
In the US, Medicare and private insurers play pivotal roles, often negotiating discounts and influencing net prices. The recent surge in biosimilar approvals encourages cost containment strategies, impacting the pricing outlook for NDC 70710-1240.
Pricing Overview
Current Pricing Dynamics
The listed wholesale acquisition cost (WAC) for similar biologics ranges from $500,000 to over $700,000 annually per patient depending on dosage and indication. Net prices, after rebates and discounts, often fall significantly below list prices.
Preliminary data suggest the drug’s current WAC aligns with upper-tier biologics, but market pressures from biosimilar entry and payer negotiations gradually enforce downward revisions.
Pricing Drivers and Constraints
- Patent and Exclusivity: Patent expiry signals upcoming price erosion.
- Therapeutic Efficacy: Superior efficacy or safety can sustain premium pricing.
- Market Penetration: Increased adoption reduces per-unit costs and supports sustainable pricing.
- Reimbursement Landscape: Payer policies directly impact net revenue realization.
- Biosimilar Competition: Anticipated biosimilar approval and commercialization considerably influence price expectations.
Future Price Projections
Short-term Outlook (1-2 Years)
With the upcoming patent expiration or biosimilar approvals, expect a 15-25% reduction in net prices within the next 12-24 months. Market share gains by biosimilars could compress prices further, especially in the US and European markets. Manufacturer-led negotiations, patient assistance programs, and value-based pricing strategies will shape the pricing trajectory.
Medium to Long-term Outlook (3-5 Years)
As biosimilars establish market footholds, biologic prices could decline by 30-50%, aligning with historical patterns observed in similar therapeutic classes. Innovation in delivery methods, efficacy enhancements, or combination therapies may enable premium pricing and mitigate market erosion.
Furthermore, global expansion, especially into emerging markets where biologic accessibility improves, could stabilize revenue streams despite pricing pressures. Utilization growth driven by expanded indications and increased awareness should offset some price declines over the medium term.
Market Opportunities and Risks
Opportunities:
- Leveraging biosimilar pipelines and cost advantages
- Expanding indications via clinical trials to grow patient populations
- Strategic partnerships with payers for value-based pricing
Risks:
- Accelerated biosimilar approvals constraining revenue
- Stringent regulatory changes impacting market access
- Pricing caps or reimbursement cuts in key markets
- Competitive innovations from next-generation therapies
Key Takeaways
-
Market Growth Driven by Demand: The autoimmune biologics market is expanding, with increasing prevalence and improved awareness fueling demand for therapies like NDC 70710-1240.
-
Competitive Pressures Will Impact Prices: Biosimilar entry is imminent or ongoing, likely resulting in significant price reductions over the next 3-5 years.
-
Pricing Strategy Must Adapt: Manufacturers should focus on demonstrating clinical differentiation, expanding indications, and engaging with payers for value-based arrangements.
-
Global Market Expansion Offers Hope: Emerging markets present growth opportunities, potentially buffering pricing pressures in mature markets.
-
Regulatory Monitoring Is Critical: Staying informed about patent status, exclusivity periods, and biosimilar approvals determines timing and magnitude of pricing shifts.
FAQs
1. What factors most influence the price of NDC 70710-1240?
The price is predominantly driven by patent status, competitive biosimilar entry, clinical efficacy, payer negotiations, and regulatory changes.
2. How soon can biosimilar competition affect the pricing of this drug?
Biosimilars for similar biologics are already approved or will be in the next 1-2 years, with potential price impacts beginning shortly thereafter.
3. Are there opportunities for upward pricing?
Yes, through indication expansion, clinical differentiation, and value-based payer agreements, particularly if the drug demonstrates superior efficacy or safety.
4. Which markets present the greatest growth potential?
The US, Europe, and emerging markets like China and India offer significant growth opportunities, driven by increasing access and rising disease prevalence.
5. How should manufacturers prepare for future pricing challenges?
Investing in clinical innovation, fostering strong payer relationships, diversifying indications, and exploring partnerships for biosimilar development are key strategies.
References
- FDA Biosimilar Approvals and Market Data. (2022). U.S. Food and Drug Administration.
- Evaluate Pharma Reports. (2022). Global Biologic Market Trends.
- MarketWatch Analysis. (2022). Biologics Market Growth and Competitive Dynamics.
- Pharmaceutical Pricing Reports. (2022). Impact of Biosimilars on Indicated Therapies.
- Healthcare Payer Reimbursement Trends. (2022). Pricing and Formulary Strategies in Autoimmune Indications.
In conclusion, NDC 70710-1240 sits within a dynamic, highly competitive market characterized by robust growth opportunities but also significant pricing pressures from biosimilar entrants. Strategic positioning focusing on clinical advantages and indication expansion will be crucial for maximizing its market potential and price sustainability.
More… ↓
